-
1.发明公开公开(公告)号：US20240350506A1
公开(公告)日：2024-10-24
申请号：US18579906
申请日：2022-07-18
发明人： Li Juan CHEN
IPC分类号： A61K31/5377 , A61K31/52 , A61K47/18 , A61K47/26 , A61K47/40
CPC分类号： A61K31/5377 , A61K31/52 , A61K47/183 , A61K47/26 , A61K47/40
摘要： A preparation of a histone deacetylase inhibitor contains the histone deacetylase inhibitor and an excipient. The excipient is at least one of or a combination of two or more of cyclodextrin, arginine and meglumine. The preparation significantly increases the solubility of the histone deacetylase inhibitor in water, and improves the stability and retains the excellent anti-tumor activity of the histone deacetylase inhibitor.
-
公开(公告)号：US12121566B2
公开(公告)日：2024-10-22
申请号：US16777625
申请日：2020-01-30
发明人： Jeffrey D. Kent , Brian Lamoreaux
CPC分类号： A61K38/44 , A61K9/0053 , A61K31/52 , A61P19/06
摘要： The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and azathioprine immunosuppressive therapy. Also provided are methods of reducing intolerance or enhancing immuno-tolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and azathioprine immunosuppressive therapy.
-
公开(公告)号：US20240343729A1
公开(公告)日：2024-10-17
申请号：US18293645
申请日：2022-07-29
IPC分类号： C07D487/04 , A61K31/52 , A61K31/5377 , A61K31/541 , A61P1/00 , A61P1/04 , C07D471/04 , C07D473/34 , C07D519/00
CPC分类号： C07D487/04 , A61K31/52 , A61K31/5377 , A61K31/541 , A61P1/00 , A61P1/04 , C07D471/04 , C07D473/34 , C07D519/00
摘要： The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, and/or N-oxide thereof. The invention also relates to the processes for the preparation of those compounds, pharmaceutical compositions comprising those compounds, and the uses of those compounds in treating diseases or conditions associated with inflammatory bowel disease (IBD), in particular ulcerative colitis (UC) and Crohn's disease (CD).
-
公开(公告)号：US20240342181A1
公开(公告)日：2024-10-17
申请号：US18299416
申请日：2023-04-12
申请人： Xygenyx Inc.
发明人： Alexy Goldstein
IPC分类号： A61K31/52 , A61K9/00 , A61K31/20 , A61K31/201 , A61K31/205
CPC分类号： A61K31/52 , A61K9/0053 , A61K31/20 , A61K31/201 , A61K31/205
摘要： A method and compositions of treatment for improving metabolic performance using supplementation, comprising the step of applying a supplement formulation to a human subject via a selected administration route, the supplement formulation comprising therapeutically effective amounts of a plurality of medium-chain triglycerides, a plurality of amino acids, and zeatin. The plurality of medium-chain triglycerides may comprise caprylic acid, and the plurality of amino acids may comprise carnitine which may be provided in the form of L-carnitine fumarate.
-
公开(公告)号：US20240335478A1
公开(公告)日：2024-10-10
申请号：US18288241
申请日：2022-04-22
发明人： SHAFIQUE KESHAVJEE , MARCELO CYPEL , MINGYAO LIU , STEPHEN JUVET , KUMI MESAKI
IPC分类号： A61K35/42 , A61K31/52 , A61K31/573 , A61K38/13 , A61P37/06 , C07K14/47 , C07K14/54 , C12N9/22 , C12N15/11 , C12N15/90
CPC分类号： A61K35/42 , A61K31/52 , A61K31/573 , A61K38/13 , A61P37/06 , C07K14/4703 , C07K14/5428 , C12N9/22 , C12N15/11 , C12N15/907 , C12N2310/20
摘要： The present disclosure relates generally to epigenetically and genetically modified organs and tissues and methods of producing same. In particular, the present disclosure is directed to organs and tissues that have been epigenetically and/or genetically modified at one or multiple loci to control inflammation-regulating or immune-regulating gene expression and thereby improve the condition of the organs and tissues.
-
公开(公告)号：US20240335373A1
公开(公告)日：2024-10-10
申请号：US18591127
申请日：2024-02-29
CPC分类号： A61K9/0036 , A61F6/08 , A61K31/52 , A61K31/565 , A61L31/125 , A61L31/16 , A61P31/18 , A61L2300/602
摘要： A post-fabrication method for drug loading a medical device with an active pharmaceutical ingredient (API). Such medical devices can include a polymer matrix, where the polymer matrix, after exposure to a loading solution with the API, can exhibit a degree of swelling of the polymer matrix and/or a degree of swelling in which the polymer matrix increases in a dimension along an axis. Medical devices including a polymer matrix and an API are provided, where the API is loaded into the polymer matrix by adsorption and/or swelling after fabrication of the polymer matrix, wherein the medical device provides a substantially sustained release of the API for an extended period of time. The medical devices include intravaginal rings (IVR). Methods of treating a subject using the disclosed medical devices are also provided, including treating a subject with an IVR with one or more APIs loaded therein.
-
公开(公告)号：US20240325399A1
公开(公告)日：2024-10-03
申请号：US18578736
申请日：2022-01-25
发明人： Hyuk Woo LEE , Sang Yeop AHN , Hyeon Deok CHO , Yoon Pyo CHOI , Seong Wook SEO
CPC分类号： A61K31/52 , A61K9/4866 , A61P1/16
摘要： The present invention relates to a pharmaceutical composition comprising an adenosine derivative which can be usefully used for preventing or treating cholangitis or a liver disease caused by cholangitis, and the composition comprises a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
-
公开(公告)号：US20240293415A1
公开(公告)日：2024-09-05
申请号：US18644709
申请日：2024-04-24
发明人： Jeffery L. KUTOK
IPC分类号： A61K31/52 , A61K31/497 , A61K39/00 , A61K39/395 , A61P35/00 , C07K16/28
CPC分类号： A61K31/52 , A61K31/497 , A61K39/39566 , A61P35/00 , C07K16/2803 , C07K16/2818 , A61K2039/505 , C07K2317/21 , C07K2317/24
摘要： Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a checkpoint modulator, 2) an XPO1 inhibitor, 3) an anti-CD19 antibody, 4) a TLR agonist, 5) a STING agonist, or 6) a Flt3 ligand, or a combination thereof. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer.
-
公开(公告)号：US12076329B2
公开(公告)日：2024-09-03
申请号：US17332865
申请日：2021-05-27
申请人： The Regents of the University of California , Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. , Cornell University
IPC分类号： A61K31/655 , A61F9/00 , A61K9/00 , A61K31/52 , A61K35/76 , A61K38/16 , A61K47/40 , A61K47/60 , A61K47/65 , A61K47/68 , A61P27/02
CPC分类号： A61K31/655 , A61F9/0008 , A61K9/0048 , A61K31/52 , A61K35/76 , A61K38/16 , A61K47/40 , A61K47/60 , A61K47/65 , A61K47/6849 , A61P27/02
摘要： The present disclosure provides a conjugate comprising an affinity agent, a branched linker, and two or more photoisomerizable regulators. The present disclosure provides compositions comprising the conjugate, as well as devices comprising the compositions. The present disclosure provides methods for enhancing visual function, the methods comprising administering the conjugate to an individual in need thereof.
-
公开(公告)号：US20240270842A1
公开(公告)日：2024-08-15
申请号：US18559195
申请日：2022-05-06
申请人： Viela Bio, Inc
IPC分类号： C07K16/28 , A61K9/00 , A61K31/365 , A61K31/436 , A61K31/52 , A61K31/5377 , A61K31/573 , A61K39/395 , A61P37/06
CPC分类号： C07K16/2803 , A61K9/0019 , A61K31/365 , A61K31/436 , A61K31/52 , A61K31/5377 , A61K31/573 , A61K39/3955 , A61P37/06 , C07K2317/24
摘要： Methods for using an anti-CD19 antibody to treat autoimmune disease are disclosed herein. In particular, the disclosure provides for the use of Inebilizumab, a humanized, affinity-optimized, afucosylated IgG1 kappa monoclonal antibody to treat myasthenia gravis.
-
-
-
-
-
-
-
-
-
搜索结果
4243 条记录 (耗时 0.01 秒)
